Response to Comments: Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis

This document is an administrative Response to Comments regarding the Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis LCD and does not itself specify clinical coverage criteria. It announces the official notice period beginning October 16, 2018, with the final LCD determination effective December 1, 2018, and notes that public and provider comments were solicited as part of LCD development.

"Official notice period for the final LCD begins October 16, 2018, and the final determination becomes effective December 1, 2018."

Sign up to see full coverage criteria, indications, and limitations.